← Back to list
Gene Expression Profiling for Cancer Indications - Medicare Advantage (Revised)
Act
by May 1, 2026
Effective date
May 1, 2026
Identified
Jun 24, 2026
Summary
Humana Medicare Advantage has updated their gene expression profiling policy for cancer indications, effective May 1, 2026. This policy covers various molecular diagnostic tests and biomarkers for multiple cancer types including breast, prostate, lung, colon, melanoma, and bladder cancers.
Get alerts when payers change rules like this one
We check Humana and other payers every day and email you when a change matches your specialty and state.
Get Humana alertsPolicy Monitoring is free. No card required.
What to do
by May 1, 2026 · 3 steps
01Review and update prior authorization procedures for gene expression profiling tests used in cancer diagnosis and treatment planning.
02Billing team should verify coverage requirements for molecular diagnostic tests against the updated policy guidelines.
03Ensure documentation requirements align with new policy standards for all cancer-related genetic testing services.
Original notice
Gene Expression Profiling for Cancer Indications - Medicare Advantage (Revised)
mcp.humana.com · Always check the source before changing claims.
Related changes
See all Humana changes →Gene Expression Profiling for Cancer Indications - Medicare Advantage (Revised)MediumEffective Oct 12, 2026 · Medicare AdvantageGene Expression Profiling for Cancer Indications - Medicare Advantage (Revised)HighEffective Oct 1, 2026 · Medicare AdvantageGene Expression Profiling for Noncancer Indications - Medicare Advantage (Revised)MediumEffective Aug 3, 2026 · Medicare AdvantageGene Expression Profiling for Noncancer Indications - Medicare Advantage (Revised)MediumEffective Nov 3, 2025 · Medicare AdvantageBrowse every Humana change in the policy list